Shanghai Aopen Medical Technology
A manufacturer of medical robots
About Shanghai Aopen Medical Technology
Shanghai Aopen Medical Technology Co., Ltd., founded in 2017, is a company focused on the development, manufacturing, and sales of medical robots. The firm was established by Dr. Liu Daozhi, who also serves as the founder and executive partner of BlueRun Ventures (山蓝资本). Dr. Liu holds a Ph.D. from Nankai University and completed postdoctoral research at the University of Oxford. His prior experience includes serving as Senior Vice President of Emerging Businesses and R&D at MicroPort Scientific Corporation, and as General Manager of MicroPort Orthopedics. This background in medical devices and venture capital has shaped the company's direction.
The company operates in the high-tech medical device market, specifically targeting the field of vascular interventional surgical robotics. Its primary clients are hospitals and vascular surgeons. Aopen Medical's business model centers on the research, development, and eventual sale of its robotic surgical systems to these medical institutions. The company has successfully raised significant capital through multiple funding rounds, including a Series C in April 2025, a Series B in August 2021, and a Series A in September 2020, to finance clinical trials, R&D, and regulatory certifications.
Aopen Medical's flagship product is the ALLVAS® pan-vascular interventional surgical robot. This system is designed to assist surgeons in performing a wide range of procedures, such as coronary, peripheral, neurological, and tumor interventions. A key feature of the ALLVAS® system is its compatibility with a full range of interventional surgical consumables, a platform-based design intended to address limitations of other systems. The robot aims to enhance operational precision and stability while allowing surgeons to operate remotely, thereby reducing their exposure to X-ray radiation. The system also incorporates features for full-process automation and a surgical navigation system. In April 2023, the ALLVAS® robot was used to complete a remote robotic-assisted PCI (Percutaneous Coronary Intervention) surgery, a notable achievement for the company.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Open positions
- None listed
- Industry
- Robotics
- Sector
- Medical Robots, DT and LS
- Technology
- Hardware, Deep Tech
- Business model
- Manufacturing
- Client focus
- B2B
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES C✓Equity / VC | Apr 2025 | $14M | $55M | Sunland fund | ↗ |
Growth signals
Latest recorded traffic for Shanghai Aopen Medical Technology is 230 monthly website visits.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Shanghai Aopen Medical Technology in the Pudong ecosystem
The Shanghai Aopen Medical Technology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later1 investor entered at this stage
Sunland fund
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Shanghai Aopen Medical Technology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Shanghai Aopen Medical Technology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









